JPMorgan Chase & Co. Has $39.09 Million Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

JPMorgan Chase & Co. lessened its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 0.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 903,415 shares of the company’s stock after selling 6,661 shares during the period. JPMorgan Chase & Co.’s holdings in Establishment Labs were worth $39,091,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Principal Financial Group Inc. acquired a new stake in Establishment Labs during the 2nd quarter worth $593,000. First Turn Management LLC acquired a new position in shares of Establishment Labs during the 2nd quarter worth about $16,812,000. William Blair Investment Management LLC increased its stake in shares of Establishment Labs by 14.5% in the 2nd quarter. William Blair Investment Management LLC now owns 481,572 shares of the company’s stock valued at $21,883,000 after acquiring an additional 60,848 shares during the last quarter. Sofinnova Investments Inc. boosted its position in shares of Establishment Labs by 204.1% during the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company’s stock worth $19,505,000 after purchasing an additional 288,082 shares in the last quarter. Finally, Divisadero Street Capital Management LP acquired a new position in Establishment Labs in the second quarter valued at about $5,829,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

ESTA has been the topic of several recent analyst reports. Stephens upgraded Establishment Labs to a “strong-buy” rating in a report on Monday, December 2nd. Citigroup boosted their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Finally, BTIG Research lifted their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Establishment Labs currently has a consensus rating of “Buy” and a consensus price target of $60.60.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $46.26 on Monday. Establishment Labs Holdings Inc. has a one year low of $24.43 and a one year high of $60.12. The stock has a market cap of $1.30 billion, a P/E ratio of -17.93 and a beta of 1.16. The company has a fifty day moving average price of $44.09 and a two-hundred day moving average price of $43.63. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.